Top Executives Leaving JPMorgan, Avon
Another top executive is leaving JPMorgan Chase: one of two COOs will become the ninth exec to leave in the past year and a half. And Avon chairman Fred Hassan has resigned.
drug companies
Bayer to Buy Calif. Birth-Control Device Maker for $1B
Bayer has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider.
Abbott Labs Posts Strong First-Quarter Growth
Abbott Labs reports higher earnings from continuing operations, as demand for its nutritional and diagnostic products offset declining sales of the company's medical devices.
Bristol-Myers Squibb Expansion to Add 350 Jobs
Drugmaker Bristol-Myers Squibb plans to spend about $250 million expanding a manufacturing complex it opened in 2009 for biologic treatments.
Drugmaker Eli Lilly Plans to Cut Hundreds of Sales Jobs
Eli Lilly plans to cut hundreds of workers from its U.S. sales force as the drugmaker prepares to deal with the loss of patent protection for two more top-selling drugs.
Is Your Doctor on Big Pharma's Payroll?
Drug companies spend hundreds of millions of dollars a year to influence doctors' prescribing habits -- money that often goes directly into physicians' pockets for "consulting fees" and "educational presentations." Wondering if your doc is one of them? The nonprofit journalists at ProPublica can tell you.
Big Pharma Ads Flaunt FDA Rules
Officially, it's the FDA's job to ensure that pharmaceutical ads adhere to guidelines. But the agency's annual compliance budget is $9 million, while drug companies spend $58 billion a year on marketing. So it comes as no surprise that only 18% of ads are in compliance with the rules. But it's still disturbing: This is your health.
Swine Flu Response Wasn't Influenced by Vaccine Makers
During the H1N1 swine flu pandemic, much criticism was leveled at World Health Organization officials, accusing their response of being too heavily influenced by the pharmaceutical industry. But according to a panel of independent experts, that wasn't the case.
Why Samsung Electronics Should Say No to Drugs
Samsung Electronics is known for its smartphones, TVs and memory chips. Now it wants to tackle biopharmaceuticals, on Friday announcing a new joint venture to produce drugs to treat cancer and arthritis. Here's why the move could prove an ill-needed distraction for the electronics giant.
The Problem with Fast-Tracking Drug Approvals: Pharmas Fail to Follow Up
To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs -- those that address unmet medical needs -- based on fewer trials than usual. But it turns out that many of the pharmaceutical companies fail to conduct follow-up trials to prove the drugs work.
More Proof That Whistleblowing on Medicaid Fraud Works
Whistleblowing firm Ven-A-Care has recovered $2 billion for taxpayers by suing drug companies that overcharge the government and create windfalls for participating pharmacies. It also has made $380 million for itself. What's the problem with that?
The New-Drug Pipeline: U.S. Biotechs Lead the Way
The U.S. leads the world in creating new drugs, and big pharmaceutical companies companies play an important role. But according to a new study, a unique system of collaboration between universities and small biotech firms is the key to the system.
Sanofi Is in No Rush to Reach Deal With Genzyme
Sanofi-Aventis CEO Chris Viehbacher said Wednesday that he believes his French pharmaceutical company will eventually buy U.S. biotech company Genzyme at a reasonable price. However, he expects it will take some time to agree on a deal, and he won't rush into anything.
Four Pharmacy Stocks Getting a Boost From Reform
Health care reform will benefit millions of people, and many companies stand to gain as well. In particular, pharmacies and pharmacy benefit managers will garner new business as they help cover newly insured Americans. And their profits should rise accordingly.